Serum levels of CYFRA 21-1 in nasopharyngeal carcinoma and its possible role in monitoring of therapy

European Journal of Cancer Part B: Oral Oncology

Volumn 32, Issue 6, 1996, Pages 377-380

  Ho, S ^a   Leung, W T ^a   Yuen, J ^a   Johnson, P J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CYFRA 21 1; Nasopharyngeal carcinoma

Indexed keywords

CYTOKERATIN;

ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; SERUM;

FOLLOW-UP STUDIES; HUMANS; KERATINS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030294439     PISSN: 09641955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0964-1955(96)00017-6     Document Type: Article

References (10)

1. 1. Moll R, Franke WW, Schiller DL, Geiger B, Krepier R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumours and cultured cells. Cells 1982, 31, 11-24.
2. 2. Pujol J-L, Grenier J, Daures J-P, Daver A, Pujol H, Michel F-B. Serum fragment of cytokeratin sub unit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993, 53, 61-66.
3. 3. Rastel D, Ramaioli A, Cornillie F, Thirion B on behalf of the CYFRA 21-1 Multicentre Study Group. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. Eur J Cancer 1994, 30A, 601-606.
4. 4. Gaast A, Schoenmarkers CHH, Kok TC, Blijenberg BG, Cornillie F, Splinter TAW. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. Br J Cancer 1994, 69, 525-528.
5. 5. Hong Kong Cancer Registry, 1989 Annual Statistical Report. Hong Kong Hospital Authority, March 1993.
6. 6. Lee AWM, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and pattern of failure. Int J Radiat Oncol Biol Phys 1992, 23, 261-270.
7. 7. Ho JHC. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978, 4, 183-198.
8. 8. Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976, 17, 1-7.
9. Q. De-Vathaire F, Sancho-Garnier H, De-The H, et al. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicentre follow-up study. Int J Cancer 1988, 42, 176-181.
10. 10. Lai KN, Ho S, Leung JCK, Tsao SY. Soluble interleukin-2 receptors in patients with nasopharyngeal carcinoma. Cancer 1991, 67, 2180-2185.